Key Insights:
- Mainz Biomed’s eAArly DETECT test received the Poster of Distinction at Digestive Disease Week 2024. The test showed 97% sensitivity and specificity for colorectal cancer and 82% sensitivity for advanced adenomas.
- The test combines the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers and an AI algorithm, enabling precise differentiation between various colorectal conditions.
- These advancements support a shift from cancer detection to prevention, improving non-invasive colorectal cancer screening methods and potentially reducing mortality rates.
Mainz Biomed’s eAArly DETECT test demonstrates significant improvements in non-invasive colorectal cancer screening, offering high sensitivity and specificity, and supporting a shift towards prevention.